Adagio Therapeutics, Inc.
https://adagiotx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adagio Therapeutics, Inc.
Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid
The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.
Can Adagio’s Adintrevimab Hold Up Against Omicron BA.2?
The company will seek an EUA for the COVID-19 antibody after trial data indicated efficacy against Omicron, but studies have called into question its potency against the rapidly expanding subvariant.
Finance Watch: Financial Market Turmoil Ends Amicus SPAC Deal For Gene Therapy Spinout
Public Company Edition: As their stock prices plummet, Adagio reshuffles its research plan and names a new CEO, while Yumanity restructures and seeks strategic alternatives. Also, Bristol sells $6bn worth of notes, Amgen issues $750m green bond, and Inhibrx and Amryt amend and refinance debt.
Big Health Digital Therapeutics Rings In 2022 With $75M Financing, FDA Alum On Board
Big Health will use its $75m in new funding to scale the business, with plans to launch six new digital therapeutics by 2024. Former US FDA official Anand Shah will join its board of directors.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule